Most medium and small sized pharmaceutical companies in India would like to upgrade their facilities but face many hurdles. A quick glance at some suggestions from industry associations and MSME players reveals that the wish list for revival ranges from increased financial incentives to having a larger voice in policy framing initiatives. By Usha Sharma
– Dr PV Appaji, Director General, Pharmexcil
– SR Vaidya, Chairman, MSME Sub Committee, IDMA
– SV Veerramani, President, Indian Drug Manufacturers Association (IDMA)
– BG Barve, Joint Managing Director, Blue Cross Laboratories
– Kapil Jhaver, President & Managing Director, TIL Healthcare
